RecruitingNot Applicable

Meu-cinn for Gastric Mucosal Health in Adults With Functional Dyspepsia

South Korea100 participantsStarted 2024-12-04

Plain-language summary

This clinical trial aims to determine whether Meu-cinn promotes gastric mucosal health in adults with functional dyspepsia and to assess its safety. The main questions are: * Does Meu-cinn promote gastric mucosal health in participants? * What side effects occur when participants take Meu-cinn?

Who can participate

Age range

19 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Rome IV-based functional dyspepsia- Exclusion Criteria: * Patients with gastrointestinal symptoms requiring immediate drug treatment. * Individuals with a history of hypersecretory gastric disorders like Zollinger-Ellison syndrome. * Individuals who received Helicobacter pylori eradication therapy within 4 weeks prior to the trial. * Individuals who have taken nonsteroidal anti-inflammatory drugs, steroids, antibiotics, aspirin, antithrombotic agents, or acid suppressants within the last month. * Individuals with a history of upper gastrointestinal surgery, stricture, bleeding, or procedures like esophageal dilation or mucosal resection within the last year. * Individuals with gastric ulcers (active or healing), duodenal ulcers (active or healing), reflux esophagitis (LA grade A or higher), or malignant tumors identified within the last 6 months through endoscopy. * Patients with uncontrolled hypertension (resting BP ≥160/100 mmHg). * Patients with uncontrolled diabetes (fasting glucose ≥160 mg/dL). * Individuals with creatinine levels ≥ 2 times the upper limit of normal at the research institution. * Individuals with aspartate aminotransferase or alanine aminotransferase levels ≥ 2 times the upper limit of normal at the research institution. * Alcohol abusers. * Individuals taking medications for psychiatric disorders (except those taking intermittent medication for sleep disorders). * Pregnant or breastfeeding women or those planning to become pregn…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The Korean version of the Gastrointestinal Symptom Rating Scale, Total score

Timeframe: From enrollment to the end of treatment at 8 weeks

Trial details

NCT IDNCT06630455

SponsorPusan National University Yangsan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-30

Contact for this trial

Sang Yeoup Lee, Professor, MD, PhD

82+55-360-2860 drsaylee@gmail.com

View on ClinicalTrials.gov More Functioanl Dyspepsia trials

Who can participate

Age range

19 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.